- Home
- TRC vs FENC Comparison
TRC vs FENC Comparison
Compare TRC & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$12.24
Company Overview
Basic Information| Metric | TRC | FENC |
|---|---|---|
| Founded | 1843 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.2M | 430.3M |
| IPO Year | 1995 | 2010 |
Fundamental Metrics
Financial Performance| Metric | TRC | FENC |
|---|---|---|
| Price | $16.48 | $12.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 177.8K | ★ 262.7K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.10 | 0.06 |
| Revenue | $37,830,000.00 | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ $164.30 | $206.50 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.31 | $5.65 |
| 52 Week High | $21.31 | $13.25 |
Technical Indicators
Market Signals| Indicator | TRC | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 45.53 | 57.63 |
| Support Level | $15.89 | $9.74 |
| Resistance Level | $16.50 | N/A |
| Average True Range (ATR) | 0.28 | 0.57 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 59.60 | 71.73 |
Price Performance
Historical Comparison TRC
FENC
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company. It has six reporting segments: Real Estate - Commercial/Industrial, Multifamily, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.